Company: TVRD
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001558370-25-011562
Chunk: 3

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1F
Chunk 3
---
Item 1. Financial Statements

TVARDI THERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS 

(Unaudited, amounts in thousands, except share and per share amounts)

​

​​​​​​​​​​As of June 30, ​As of December 31, ​​    2025    2024​Assets​​​​​​​Current assets: ​   ​  ​Cash and cash equivalents​$ 20,648​$ 31,614​   Short-term investments​​ 20,346​​ —​Prepaid expenses and other current assets​  2,136​  72​Total current assets​  43,130​  31,686​Property and equipment, net​  68​  84​Intangible assets, net​  354​  385​Operating lease right-of-use assets​  181​  216​Deferred offering costs​  —​  2,811​Other non-current assets​  17​  17​Total assets​$ 43,750​$ 35,199​​​​​​​​​Liabilities, Redeemable Convertible Preferred Stock, and Stockholders' Equity (Deficit)​   ​   ​Current liabilities:​   ​   ​Accounts payable​$ 2,425​  2,186​Accrued expenses​  8,144​  8,078​Operating lease liabilities, current portion​  109​  103​Total current liabilities​  10,678​  10,367​Operating lease liabilities, net of current portion​  145​  201​Convertible Notes​  —​  30,259​Total liabilities​  10,823​  40,827​​​​​​​​​Commitments and contingencies (Note 13)​   ​   ​​​​​​​​​Redeemable convertible preferred stock (Series A, B), $0.001 par value; 0 shares and 29,723,540 shares authorized as of June 30, 2025 and December 31, 2024, respectively; 0 shares and 3,963,910 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively; aggregate liquidation preference of $0 and $85,902 as of June